In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.
The use of conventional imaging for diagnosing coronary artery disease (CAD) in obese patients can be challenging. Attenuation artifacts can be problematic with single photon emission computed tomography (SPECT) and a lack of crisp image quality is an issue with coronary computed tomography angiography (CCTA) in this patient population, pointed out Krishna Patel, MD, in an interview at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Higher radiation dosing is also a concern with both of the aforementioned modalities, noted Dr. Patel, an assistant professor of medicine (cardiology) and population health science and policy at Icahn School of Medicine at Mount Sinai.
Accordingly, Dr. Patel and colleagues examined the use of the positron emission tomography (PET) perfusion radiotracer agent 18F-flurpiridaz in comparison to 99mTc-SPECT for detecting CAD in a subgroup analysis involving 298 obese patients (mean age of 62.1) from a phase 3 trial.
The researchers found that among obese patients, 18F-flurpiridaz demonstrated higher sensitivity rates (76.9 percent versus 69.2 percent) and specificity rates (66.9 percent versus 61.9 percent) in comparison to 99mTc-SPECT. The use of 18F-flurpiridaz also reduced radiation exposure by one-third (6.2 mSv PET) in comparison to tetrofosmin SPECT (9.9 mSv) and by one-half in comparison to sestamibi SPECT (12.4 mSv), according to Dr. Patel and colleagues.
Dr. Patel, the director of cardiac PET at Mount Sinai Morningside in New York City, added that other key benefits of 18F-flurpiridaz include a longer half-life (110 minutes) than other PET perfusion tracer agents and unit dose availability, factors that may significantly expand access to stress cardiac PET myocardial perfusion imaging.
For more insights from Dr. Patel, watch the video below.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
July 31st 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
July 31st 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
July 31st 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
July 31st 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.